Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin.
The effect of intravenous gammaglobulin (IVGG) on the immunoregulatory abnormalities found during acute Kawasaki syndrome (KS) was studied in a randomized trial of IVGG plus aspirin (ASA) versus ASA alone. Before therapy, patients in each treatment group had increased numbers of circulating HLA-DR-bearing Leu 3+ helper T cells, a deficiency of Leu 2+ suppressor/cytotoxic T cells, and increased levels of spontaneous IgG and IgM synthesis by peripheral blood mononuclear cells. There were no significant differences (P greater than 0.1) between immunologic parameters measured on day 1 and day 4 in the ASA-treated group. In contrast, patients treated with ASA plus IVGG had by day 4 a highly significant decrease in HLA-Dr+ Leu 3+ helper T cells (P less than 0.001), an increase in Leu 2+ suppressor/cytotoxic T cells (P less than 0.01), and a decrease in spontaneous IgG (P less than 0.01) and IgM synthesis (P less than 0.001). These changes were associated with a reduction in the secretion of T cell-derived B cell helper factors (P less than 0.001). These findings indicate that treatment with IVGG suppresses the marked T and B cell activation found in patients with acute KS.
D000911:Antibodies, Monoclonal; D001241:Aspirin / Q000627:therapeutic use*; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007262:Infusions, Intravenous; D008213:Lymphocyte Activation; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000276:immunology* / Q000628:therapy; D011897:Random Allocation; D012016:Reference Values; D013601:T-Lymphocytes / Q000145:classification / Q000276:immunology; D005719:gamma-Globulins / Q000008:administration & dosage / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D006684:HLA-DR Antigens; D005719:gamma-Globulins; D001241:Aspirin